16:07:17 EDT Fri 10 May 2024
Enter Symbol
or Name
USA
CA



Medicure Inc (2)
Symbol MPH
Shares Issued 10,436,313
Close 2023-07-21 C$ 1.25
Market Cap C$ 13,045,391
Recent Sedar Documents

Medicure to release Q2 2023 results July 28

2023-07-24 19:11 ET - News Release

Dr. Albert Friesen reports

MEDICURE TO PRESENT FINANCIAL RESULTS ON JULY 31, 2023 CALL AT 8:30 AM ET FOR QUARTER ENDED JUNE 30, 2023

Medicure Inc. will present the 2023 Q2 financial results on a conference call on July 31, 2023, at 8:30 a.m. Eastern Time. The Q2 financials will be filed after closing July 28, 2023.

Conference call info:

Topic:  Medicure's Q2 2023 results

Call date:  Monday, July 31, 2023

Time:  7:30 a.m. Central Time (8:30 a.m. Eastern Time)

Toll-free:  1-888-506-0062

International:  1-973-528-0011

Participant access code:  599508

Webcast:   This conference call will be webcast live over the Internet.

You may request international country-specific access information by e-mailing the company in advance. Management will accept and answer questions related to the financial results and operations during the question-and-answer period at the end of the conference call. A recording of the call will be available following the event at the company's website.

About Medicure Inc.

Medicure is a pharmaceutical company focused on the development and commercialization of therapies for the United States cardiovascular market. The present focus of the company is the marketing and distribution of Aggrastat (tirofiban hydrochloride) injection and Zypitamag (pitavastatin) tablets in the United States, where they are sold through the company's U.S. subsidiary, Medicure Pharma Inc. Medicure also operates Marley Drug Inc., a pharmacy located in North Carolina that offers an extended supply drug program serving all 50 states, Washington, D.C., and Puerto Rico. Marley Drug is committed to improving the health status of its patients and the communities they serve while reducing overall health care costs for employers and other health care consumers.

We seek Safe Harbor.

© 2024 Canjex Publishing Ltd. All rights reserved.